NASDAQ:ANEB Anebulo Pharmaceuticals (ANEB) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free ANEB Stock Alerts $2.70 -0.09 (-3.22%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$2.70▼$2.7050-Day Range$2.40▼$3.0452-Week Range$1.62▼$4.05Volume387 shsAverage Volume5,082 shsMarket Capitalization$69.30 millionP/E RatioN/ADividend YieldN/APrice Target$6.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Anebulo Pharmaceuticals alerts: Email Address Anebulo Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside146.6% Upside$6.67 Price TargetShort InterestHealthy0.22% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.47) to ($0.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.35 out of 5 starsMedical Sector725th out of 914 stocksPharmaceutical Preparations Industry331st out of 418 stocks 3.5 Analyst's Opinion Consensus RatingAnebulo Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAnebulo Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.22% of the float of Anebulo Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAnebulo Pharmaceuticals has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Anebulo Pharmaceuticals has recently increased by 6.91%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAnebulo Pharmaceuticals does not currently pay a dividend.Dividend GrowthAnebulo Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANEB. Previous Next 0.6 News and Social Media Coverage News SentimentAnebulo Pharmaceuticals has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Anebulo Pharmaceuticals this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anebulo Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders85.90% of the stock of Anebulo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 28.40% of the stock of Anebulo Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Anebulo Pharmaceuticals are expected to decrease in the coming year, from ($0.47) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anebulo Pharmaceuticals is -6.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anebulo Pharmaceuticals is -6.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnebulo Pharmaceuticals has a P/B Ratio of 6.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Anebulo Pharmaceuticals Stock (NASDAQ:ANEB)Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Read More ANEB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANEB Stock News HeadlinesApril 17, 2024 | morningstar.comAnebulo Pharmaceuticals Inc 214April 2, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Acrivon Therapeutics, Inc. (ACRV), Abivax SA Sponsored ADR (ABVX)April 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.February 26, 2024 | msn.comMilestone rallies 23% on FDA update for tachycardia drugFebruary 16, 2024 | markets.businessinsider.comAnebulo Pharmaceuticals: Strong Buy Rating Amid Promising Clinical Advances and Rapid FDA TrackFebruary 15, 2024 | msn.comNew Debt & Financing Risk for Anebulo Pharmaceuticals, Inc. – What’s the Latest?February 14, 2024 | msn.comSubstance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication DrugFebruary 13, 2024 | finance.yahoo.comAnebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent UpdatesApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.January 20, 2024 | benzinga.comAnebulo Pharmaceuticals Stock (NASDAQ:ANEB) Dividends: History, Yield and DatesJanuary 8, 2024 | finance.yahoo.comAnebulo Pharmaceuticals, Inc. (ANEB)December 17, 2023 | nasdaq.comAnebulo Pharmaceuticals (FRA:214) Price Target Increased by 21.00% to 6.80December 9, 2023 | morningstar.comAnebulo Pharmaceuticals Inc ANEBNovember 21, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: 60 Degrees Pharmaceuticals, Inc. (SXTP) and Brainsway (BWAY)November 17, 2023 | markets.businessinsider.comBuy Recommendation for Anebulo Pharmaceuticals: Promising Financial Outlook and Potential Breakthrough in Acute Cannabis Intoxication TreatmentNovember 15, 2023 | msn.comAnebulo Pharmaceuticals GAAP EPS of -$0.10 beats by $0.02November 14, 2023 | finance.yahoo.comAnebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent UpdatesNovember 6, 2023 | finance.yahoo.comHere's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn SituationOctober 19, 2023 | msn.comAre Medical Stocks Lagging Anebulo Pharmaceuticals (ANEB) This Year?October 11, 2023 | benzinga.comDirector at Anebulo Pharmaceuticals Acquires Company Stock Options Worth 26,097 SharesOctober 6, 2023 | marketwatch.comAnebulo Pharmaceuticals Names Richie Cunningham as CEOOctober 6, 2023 | finance.yahoo.comAnebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of DirectorsOctober 6, 2023 | finance.yahoo.comAnebulo Pharmaceuticals Announces New CEOSeptember 25, 2023 | msn.comHC Wainwright & Co. Reiterates Anebulo Pharmaceuticals (ANEB) Buy RecommendationSeptember 25, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Anebulo Pharmaceuticals (ANEB)September 23, 2023 | nasdaq.comMaxim Group Initiates Coverage of Anebulo Pharmaceuticals (ANEB) with Buy RecommendationSeptember 22, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Aurinia Pharmaceuticals (AUPH) and Aquestive Therapeutics (AQST)See More Headlines Receive ANEB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/13/2024Today4/27/2024Next Earnings (Estimated)5/09/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ANEB CUSIPN/A CIK1815974 Webwww.anebulo.com Phone512-598-0931FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Stock Price Target$6.67 High Stock Price Target$8.00 Low Stock Price Target$6.00 Potential Upside/Downside+146.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,730,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-109.40% Return on Assets-98.40% Debt Debt-to-Equity RatioN/A Current Ratio6.72 Quick Ratio6.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / Book6.59Miscellaneous Outstanding Shares25,633,000Free Float3,614,000Market Cap$69.30 million OptionableNot Optionable Beta-1.00 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Joseph F. Lawler M.D. (Age 52)Ph.D., Founder & Chairman Comp: $11kDr. Kenneth C. Cundy Ph.D. (Age 65)Chief Scientific Officer Comp: $425.15kMr. Richard Anthony Cunningham (Age 53)CEO & Director Mr. Daniel V. George (Age 54)Principal Accounting Officer, Acting CFO & Secretary Mr. Scott L. AndersonHead of Investor Relations & Public AffairsKey CompetitorsLandos BiopharmaNASDAQ:LABPJourney MedicalNASDAQ:DERMCarisma TherapeuticsNASDAQ:CARMViveon Health AcquisitionNYSE:VHAQAssembly BiosciencesNASDAQ:ASMBView All Competitors ANEB Stock Analysis - Frequently Asked Questions Should I buy or sell Anebulo Pharmaceuticals stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anebulo Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANEB shares. View ANEB analyst ratings or view top-rated stocks. What is Anebulo Pharmaceuticals' stock price target for 2024? 3 brokers have issued 12 month target prices for Anebulo Pharmaceuticals' stock. Their ANEB share price targets range from $6.00 to $8.00. On average, they anticipate the company's share price to reach $6.67 in the next twelve months. This suggests a possible upside of 146.6% from the stock's current price. View analysts price targets for ANEB or view top-rated stocks among Wall Street analysts. How have ANEB shares performed in 2024? Anebulo Pharmaceuticals' stock was trading at $2.42 at the start of the year. Since then, ANEB shares have increased by 11.7% and is now trading at $2.7036. View the best growth stocks for 2024 here. Are investors shorting Anebulo Pharmaceuticals? Anebulo Pharmaceuticals saw a increase in short interest in April. As of April 15th, there was short interest totaling 20,100 shares, an increase of 6.9% from the March 31st total of 18,800 shares. Based on an average daily volume of 5,600 shares, the short-interest ratio is currently 3.6 days. Approximately 0.2% of the company's stock are short sold. View Anebulo Pharmaceuticals' Short Interest. When is Anebulo Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ANEB earnings forecast. How were Anebulo Pharmaceuticals' earnings last quarter? Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) announced its quarterly earnings results on Tuesday, February, 13th. The company reported ($0.11) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.11). When did Anebulo Pharmaceuticals IPO? Anebulo Pharmaceuticals (ANEB) raised $21 million in an IPO on Friday, May 7th 2021. The company issued 3,000,000 shares at a price of $6.00-$8.00 per share. The Benchmark Company acted as the underwriter for the IPO. How do I buy shares of Anebulo Pharmaceuticals? Shares of ANEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ANEB) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithJeff Bezos Just Humiliated Elon MuskInvestorPlaceBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
